Mechanistic studies targeting SP140’s immune pathways (e.g., PD-L1, TRIM22) and SP100’s DNA repair functions in underrepresented cancers (e.g., BLCA, OSCC) could refine therapeutic applications. This evidence concerns the gene SP140 and bladder transitional cell carcinoma.